Arcutis Biotherapeutics Inc. (ARQT) PT Raised to 'Street High' $80 at Cowen

Cowen analyst Ken Cacciatore raised the price target on Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) to a 'Street High' $80.00 (from $55.00) while maintaining an Outperform rating.

The analyst commented, "Arcutis announced positive pivotal Phase III results for ARQ-151 in psoriasis, which even surpassed the impressive Phase IIb data, and we believe firmly establishes the product as the best-in-class topical with superior efficacy/ tolerability. Importantly, the other pipeline programs also continue to progress, representing additional substantial opportunities in AD & seb derm. Our PT moves to $80."

You May Also Be Interested In

• JPMorgan Downgrades Dassault Systemes SE (DSY:FP) (DASTY) to Neutral
• Banco de Sabadell SA (SAB:SM) (BNDSF) PT Raised to EUR1.85 at JPMorgan
• swedbank ab (SWEDA:SS) (SWDBF) PT Raised to SEK237 at Barclays